within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BD23_MetforminAndErtugliflozin;

model MetforminAndErtugliflozin
  extends Pharmacolibrary.Drugs.ATC.A.A10BD23;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>A10BD23</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Metformin and ertugliflozin is a fixed-dose combination oral antidiabetic medication. Metformin is a biguanide that decreases hepatic glucose production and improves insulin sensitivity, widely used as first-line therapy for type 2 diabetes mellitus. Ertugliflozin is a sodium-glucose co-transporter-2 (SGLT2) inhibitor that reduces glucose reabsorption in the kidney, leading to increased urinary glucose excretion. The combination is approved for the treatment of type 2 diabetes to improve glycemic control in adults.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic estimates for healthy adult subjects based on publicly available data for the combination product.</p><h4>References</h4><ol><li><p>Fediuk, DJ, et al., &amp; Sahasrabudhe, V (2020). Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor. <i>Clinical pharmacokinetics</i> 59(8) 949–965. DOI:<a href=&quot;https://doi.org/10.1007/s40262-020-00875-1&quot;>10.1007/s40262-020-00875-1</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32337660/&quot;>https://pubmed.ncbi.nlm.nih.gov/32337660</a></p></li><li><p>Kalgutkar, AS, et al., &amp; Robinson, RP (2011). Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus. <i>Drug metabolism and disposition: the biological fate of chemicals</i> 39(9) 1609–1619. DOI:<a href=&quot;https://doi.org/10.1124/dmd.111.040675&quot;>10.1124/dmd.111.040675</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21690265/&quot;>https://pubmed.ncbi.nlm.nih.gov/21690265</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end MetforminAndErtugliflozin;
